These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 37142868)

  • 1. Multiregional radiomics of brain metastasis can predict response to EGFR-TKI in metastatic NSCLC.
    Fan Y; Wang X; Dong Y; Cui E; Wang H; Sun X; Su J; Luo Y; Yu T; Jiang X
    Eur Radiol; 2023 Nov; 33(11):7902-7912. PubMed ID: 37142868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative MRI-Based Radiomics of Brain Metastasis to Assess T790M Resistance Mutation After EGFR-TKI Treatment in NSCLC.
    Fan Y; He L; Yang H; Wang Y; Su J; Hou S; Luo Y; Jiang X
    J Magn Reson Imaging; 2023 Jun; 57(6):1778-1787. PubMed ID: 36165534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiomics for prediction of response to EGFR-TKI based on metastasis/brain parenchyma (M/BP)-interface.
    Fan Y; Zhao Z; Wang X; Ai H; Yang C; Luo Y; Jiang X
    Radiol Med; 2022 Dec; 127(12):1342-1354. PubMed ID: 36284030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Habitat-Based Radiomics for Predicting EGFR Mutations in Exon 19 and 21 From Brain Metastasis.
    Yang C; Fan Y; Zhao D; Wang Z; Wang X; Wang H; Hu Y; He L; Zhang J; Wang Y; Liu Y; Sha X; Su J
    Acad Radiol; 2024 Sep; 31(9):3764-3773. PubMed ID: 38599906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain-Tumor Interface-Based MRI Radiomics Models to Determine EGFR Mutation, Response to EGFR-TKI and T790M Resistance Mutation in Non-Small Cell Lung Carcinoma Brain Metastasis.
    Fan Y; Wang X; Yang C; Chen H; Wang H; Wang X; Hou S; Wang L; Luo Y; Sha X; Yang H; Yu T; Jiang X
    J Magn Reson Imaging; 2023 Dec; 58(6):1838-1847. PubMed ID: 37144750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiomics evaluates the EGFR mutation status from the brain metastasis: a multi-center study.
    Cao R; Pang Z; Wang X; Du Z; Chen H; Liu J; Yue Z; Wang H; Luo Y; Jiang X
    Phys Med Biol; 2022 Jun; 67(12):. PubMed ID: 35588722
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined radiomics of primary tumour and bone metastasis improve the prediction of EGFR mutation status and response to EGFR-TKI therapy for NSCLC.
    Cheng Y; Wang H; Yuan W; Wang H; Zhu Y; Chen H; Jiang W
    Phys Med; 2023 Dec; 116():103177. PubMed ID: 38000098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Radiomics to Differentiate Brain Metastases From Lung Cancer Versus Breast Cancer, Including Predicting Epidermal Growth Factor Receptor and human Epidermal Growth Factor Receptor 2 Status.
    Shi J; Chen H; Wang X; Cao R; Chen Y; Cheng Y; Pang Z; Huang C
    J Comput Assist Tomogr; 2023 Nov-Dec 01; 47(6):924-933. PubMed ID: 37948368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved Prediction of Epidermal Growth Factor Receptor Status by Combined Radiomics of Primary Nonsmall-Cell Lung Cancer and Distant Metastasis.
    Hu Y; Geng Y; Wang H; Chen H; Wang Z; Fu L; Huang B; Jiang W
    J Comput Assist Tomogr; 2024 Sep-Oct 01; 48(5):780-788. PubMed ID: 38498926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI radiomics predicts the efficacy of EGFR-TKI in EGFR-mutant non-small-cell lung cancer with brain metastasis.
    Qi H; Hou Y; Zheng Z; Zheng M; Sun X; Xing L
    Clin Radiol; 2024 Jul; 79(7):515-525. PubMed ID: 38637187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI radiomics for predicting intracranial progression in non-small-cell lung cancer patients with brain metastases treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Qu J; Zhang T; Zhang X; Zhang W; Li Y; Gong Q; Yao L; Lui S
    Clin Radiol; 2024 Apr; 79(4):e582-e591. PubMed ID: 38310058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-liver interface in MRI of liver metastasis enables prediction of EGFR mutation in patients with lung cancer: A proof-of-concept study.
    Hou S; Wang H; Wang X; Chen H; Zhou B; Meng R; Sha X; Chang S; Wang H; Jiang W
    Med Phys; 2024 Feb; 51(2):1083-1091. PubMed ID: 37408393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases.
    Qi H; Hou Y; Zheng Z; Zheng M; Qiao Q; Wang Z; Sun X; Xing L
    BMC Cancer; 2024 Mar; 24(1):362. PubMed ID: 38515096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiomics for Detection of the EGFR Mutation in Liver Metastatic NSCLC.
    Hou S; Fan Y; Wang X; Su J; Ren M; Wu Y; Zhou J; Qu M; Luo Y; Jiang W
    Acad Radiol; 2023 Jun; 30(6):1039-1046. PubMed ID: 35907759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiomics of Spinal Metastases Originating From Primary Nonsmall Cell Lung Cancer or Breast Cancer and Ability to Predict Epidermal Growth Factor Receptor Mutation/Ki-67 Levels.
    Niu S; Zhang H; Wang X; Jiang W
    J Comput Assist Tomogr; 2023 Jul-Aug 01; 47(4):643-649. PubMed ID: 37380152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiomics signature of brain metastasis: prediction of EGFR mutation status.
    Wang G; Wang B; Wang Z; Li W; Xiu J; Liu Z; Han M
    Eur Radiol; 2021 Jul; 31(7):4538-4547. PubMed ID: 33439315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of MRI-based radiomics signatures as new markers for preoperative assessment of EGFR mutation and subtypes from bone metastases.
    Fan Y; Dong Y; Sun X; Wang H; Zhao P; Wang H; Jiang X
    BMC Cancer; 2022 Aug; 22(1):889. PubMed ID: 35964032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A deep learning model integrating multisequence MRI to predict EGFR mutation subtype in brain metastases from non-small cell lung cancer.
    Li Y; Lv X; Chen C; Yu R; Wang B; Wang D; Hou D
    Eur Radiol Exp; 2024 Jan; 8(1):2. PubMed ID: 38169047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computed tomography-based radiomics and clinical-genetic features for brain metastasis prediction in patients with stage III/IV epidermal growth factor receptor-mutant non-small-cell lung cancer.
    Zheng M; Sun X; Qi H; Zhang M; Xing L
    Thorac Cancer; 2024 Sep; 15(27):1919-1928. PubMed ID: 39101254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CT-based nomogram for early identification of T790M resistance in metastatic non-small cell lung cancer before first-line epidermal growth factor receptor-tyrosine kinase inhibitors therapy.
    Li Y; Lv X; Wang Y; Xu Z; Lv Y; Hou D
    Eur Radiol Exp; 2023 Nov; 7(1):64. PubMed ID: 37914925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.